FDA approved sonrotoclax (Beqalzi), a Bcl-2 inhibitor, in May 2026 for mantle cell lymphoma patients who have tried at least two prior therapies, positioning the drug as the second Bcl-2 inhibitor in the US. The therapy is designed by refining venetoclax’s structure to improve potency against both wild-type and mutant Bcl-2.